• Connect with us
    • Information
      • About Us
      • Contact Us
      • Careers
      • Partnerships
      • Advertise With Us
      • Authors
      • Browse Topics
      • Events
      • Disclaimer
      • Privacy Policy
    • NORTH AMERICA EDITION
      Australia
      North America
      World
    Login
    Investing News NetworkYour trusted source for investing success
    • NORTH AMERICA EDITION
      North America
      Australia
      World
    • My INN
    Videos
    Companies
    Press Releases
    Private Placements
    SUBSCRIBE
    • Reports & Guides
      • Market Outlook Reports
      • Investing Guides
    • Button
    Resource
    • Precious Metals
    • Battery Metals
    • Base Metals
    • Energy
    • Critical Metals
    Tech
    Life Science
    Pharmaceutical Market
    Pharmaceutical News
    Pharmaceutical Stocks
    • Pharmaceutical Market
    • Pharmaceutical News
    • Pharmaceutical Stocks
    pharmaceutical investing

    Repros Meets With FDA On Progress Of Proellex

    Bryan Mc Govern
    Apr. 10, 2017 09:24AM PST
    Pharmaceutical Investing

    Repros Therapeutics announced it held a meeting with the US Food and Drug Administration to discuss oral Proellex in the treatment of uterine fibroids.

    Repros Therapeutics (NASDAQ:RPRX) announced it held a meeting with the US Food and Drug Administration to discuss oral Proellex in the treatment of uterine fibroids.
    As quoted in the press release:

    Shortly before the meeting, the Company was notified that the meeting would be a type C/Guidance meeting, rather than a type B/End of phase 2 meeting as previously anticipated.  At the meeting, the FDA confirmed that Proellex® will continue on the current partial clinical hold while they consult with liver experts within the FDA regarding previously disclosed effects on the liver.  Further, the FDA agreed to accept additional information from the Company and its panel of liver experts for consideration by the FDA’s internal advisory liver team. The Company expects to submit the additional information and a proposed clinical protocol within a month.  The Company intends to announce further information following receipt of additional guidance from the FDA.

    Larry Dillaha, M.D., the Company’s President and Chief Executive Officer, commented, “The Company is pleased with the guidance received from the FDA, and while we remain on the current partial clinical hold as the FDA internally reviews our data related to the effect of Proellex® on the liver, we will proceed with our development plans by submitting additional phase 2 protocols to the FDA for their review.  We are committed to working closely with the FDA as we further our development program for Proellex®.”

    About Repros Therapeutics Inc.®

    Repros Therapeutics focuses on the development of small molecule drugs for major unmet medical needs that treat male and female reproductive disorders.

    Click here to read the full press release.

    small molecule drugsclinical holdpharmaceutical investingend of phase 2 meetingrepros therapeuticsfood and drug administration
    The Conversation (0)

    Go Deeper

    AI Powered
    A hand holding a double helix.

    Top 5 NASDAQ Genetics Stocks (Updated December 2023)

    Pharmaceutical Investing

    ProMetic Obtains FDA Clearance for Phase 2/3 Trials

    Latest News

    Seegnal Inc. Announces Extension of Maccabi Health Services Contract

    More News

    Outlook Reports

    Resource
    • Precious Metals
      • Gold
      • Silver
    • Battery Metals
      • Lithium
      • Cobalt
      • Graphite
    • Energy
      • Uranium
      • Oil and Gas
    • Base Metals
      • Copper
      • Nickel
      • Zinc
    • Critical Metals
      • Rare Earths
    • Industrial Metals
    • Agriculture
    Tech
      • Artificial Intelligence
      • Cybersecurity
      • Gaming
      • Cleantech
      • Emerging Tech
    Life Science
      • Biotech
      • Cannabis
      • Psychedelics
      • Pharmaceuticals

    Featured Pharmaceutical Investing Stocks

    Cardiol Therapeutics

    CRDL:CA
    More featured stocks

    Browse Companies

    Resource
    • Precious Metals
    • Battery Metals
    • Energy
    • Base Metals
    • Critical Metals
    Tech
    Life Science
    MARKETS
    COMMODITIES
    CURRENCIES
    ×